Replies to post #141471 on Biotech Values

[DewDiligence]

NVS—I don't think the withdrawal of NDA for SOM230 was related to the LAR formulation. The LAR formulation trial in Cushing's is few years behind and they still have ongoing trials with the S.C formulation my guess is NVS will re-file before with added data from those trials.

Thanks—that makes sense.

…[NVS] filed [SOM230] in the EU in late 2010 and approved in early 2012, isn't that a bit long?

Not unduly so, IMO.